Epic Sciences Announces Completion of $52 Million Series E Financing
Epic Sciences (Epic) announced today that the company has completed a $52 million Series E financing led by Blue Ox Healthcare Partners, with participation by Deerfield Management and Varian (NYSE: VAR).
Epic Sciences Appoints Katherine Atkinson as Chief Commercial Officer
Epic Sciences (Epic), the maker of the world’s first predictive test of drug response in prostate cancer, announced the expansion of its leadership team with the appointment of Katherine Atkinson as chief commercial officer.
Blood Test Predicts Treatment Response and Survival for Patients with Metastatic Prostate Cancer
Testing could lead to extension of life through improved clinical decision-making by identifying patients who need to switch from targeted hormonal therapy to chemotherapy
Epic Sciences Presents Single Cell Genomics Data at 10th DIA China Annual Meeting
New data demonstrates the detection of tumor mutational burden and chromosomal instability in single circulating tumor cells to develop cancer diagnostic tests for guiding immuno-oncology clinical development and decision-making.
Epic Sciences and Its Collaborators to Present New Data at ASCO 2018
New data validates clinical utility of commercially-available Oncotype DX® AR-V7 Nucleus Detect™ test and additional tests under development for predictive medicine
Epic Sciences Presents Detection and Characterization of Rare Peripheral CTC Immunogenicity and T-Cell Activation
At the 2018 AACR annual meeting, Epic Sciences presented data from two studies demonstrating the company’s “No Cell Left Behind” detection platform’s capability to analyze potential markers of response to immuno-oncology (IO) agents, such as checkpoint inhibitors, vaccines, and CAR-T therapies.
Epic Sciences and Genomic Health Announce Favorable Draft Local Coverage Determination (LCD) on Medicare Coverage for Use of the Oncotype DX® AR-V7 Nucleus Detect™ Test in Patients with Metastatic Castration-Resistant Prostate Cancer
Medicare Draft Coverage Supports Clinical Utility of the Oncotype DX AR-V7 Nucleus Detect Test, Providing 25,000 Medicare Patients with Coverage Once LCD Is Finalized